GenFleet Receives FDA Approval for Phase II Study of RIPK1 Inhibitor GFH312

Aug 18, 2022 -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has approved the clinical trial application for GFH312 in a...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials